Across TCGA pan-cancer cohorts, AGER Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AGER data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher AGER Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGER expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, UCEC, and SKCM are the cancer types where AGER Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.221	0.620	.015	12	view →
UCEC	DFS	Median	All	1.000	0.630	.033	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.560	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: AGER tumor-vs-normal RNA expression · all AGER data types